Problems with UK government’s risk sharing scheme for assessing drugs for multiple sclerosis

C. L. M. Sudlow, Carl Edward Counsell

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

The government plans to make interferon beta and glatiramer available to patients with multiple sclerosis through a risk sharing scheme, despite lack of evidence of cost effectiveness. Sudlow and colleagues argue that the money would be better spent on independent research.

Original languageEnglish
Pages (from-to)388-392
Number of pages4
JournalBritish Medical Journal
Volume326
DOIs
Publication statusPublished - 2003

Keywords

  • RANDOMIZED CONTROLLED-TRIAL
  • SECONDARY PROGRESSIVE MS
  • PLACEBO-CONTROLLED TRIAL
  • DOUBLE-BLIND
  • INTERFERON BETA-1B
  • GLATIRAMER ACETATE
  • NATURAL-HISTORY
  • CLINICAL-TRIALS
  • FINAL REPORT
  • RELAPSE RATE

Cite this

Problems with UK government’s risk sharing scheme for assessing drugs for multiple sclerosis. / Sudlow, C. L. M.; Counsell, Carl Edward.

In: British Medical Journal, Vol. 326, 2003, p. 388-392.

Research output: Contribution to journalArticle

@article{28df8f12d5cf4d31b687d27cfeb97a18,
title = "Problems with UK government’s risk sharing scheme for assessing drugs for multiple sclerosis",
abstract = "The government plans to make interferon beta and glatiramer available to patients with multiple sclerosis through a risk sharing scheme, despite lack of evidence of cost effectiveness. Sudlow and colleagues argue that the money would be better spent on independent research.",
keywords = "RANDOMIZED CONTROLLED-TRIAL, SECONDARY PROGRESSIVE MS, PLACEBO-CONTROLLED TRIAL, DOUBLE-BLIND, INTERFERON BETA-1B, GLATIRAMER ACETATE, NATURAL-HISTORY, CLINICAL-TRIALS, FINAL REPORT, RELAPSE RATE",
author = "Sudlow, {C. L. M.} and Counsell, {Carl Edward}",
year = "2003",
doi = "10.1136/bmj.326.7385.388",
language = "English",
volume = "326",
pages = "388--392",
journal = "BMJ",
issn = "0959-8146",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Problems with UK government’s risk sharing scheme for assessing drugs for multiple sclerosis

AU - Sudlow, C. L. M.

AU - Counsell, Carl Edward

PY - 2003

Y1 - 2003

N2 - The government plans to make interferon beta and glatiramer available to patients with multiple sclerosis through a risk sharing scheme, despite lack of evidence of cost effectiveness. Sudlow and colleagues argue that the money would be better spent on independent research.

AB - The government plans to make interferon beta and glatiramer available to patients with multiple sclerosis through a risk sharing scheme, despite lack of evidence of cost effectiveness. Sudlow and colleagues argue that the money would be better spent on independent research.

KW - RANDOMIZED CONTROLLED-TRIAL

KW - SECONDARY PROGRESSIVE MS

KW - PLACEBO-CONTROLLED TRIAL

KW - DOUBLE-BLIND

KW - INTERFERON BETA-1B

KW - GLATIRAMER ACETATE

KW - NATURAL-HISTORY

KW - CLINICAL-TRIALS

KW - FINAL REPORT

KW - RELAPSE RATE

U2 - 10.1136/bmj.326.7385.388

DO - 10.1136/bmj.326.7385.388

M3 - Article

VL - 326

SP - 388

EP - 392

JO - BMJ

JF - BMJ

SN - 0959-8146

ER -